COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

We have a product basket of more than 30+ ready to offer APIs with DMF & other regulatory filings across CNS, CVS, Anti-infective, Anti-diabetic segments to name a few. We also have 10 molecules in the pipeline.

To help you find the generic API you require, we've listed our generic API product range below. You can also use our 'Find an API' search tool to get quick access to the information you need.

Our range of Developed API products
Product Name Category Name CAS NO US-DMF CEP
Aprepitant Anti-Emetic 170729-80-3 26065 CEP Approved
Armodafinil Eugeroic 112111-43-0 30405
Baclofen Muscle Relaxant 1134-47-0 28455 CEP Approved
Bisoprolol Fumarate Anti-Hypertensive 104344-23-2 29123 CEP Approved
Camylofin Dihydrochloride Anti-Spasmodic 5892-41-1
Cinacalcet HCL Calcimimetic 226256-56-0 29162
Clobazam Anti-Convulsant 22316-47-8 29164
Dabigatran Etexilate Mesylate Anti-coagulant 872728-81-9 30404
Deferasirox Iron Chelator 201530-41-8 31485
Diltiazem Hydrochloride Anti-Hypertensive 33286-22-5 14713 CEP Approved
dl-Cloprostenol Sodium* Luteolytic Agent 55028-72-3 15758
Donepezil Hydrochloride Anti-Alzheimer's 120011-70-3 27650
Dronedarone Hydrochloride Anti-Arrhythmic 141625-93-6 31486
Fosaprepitant Dimeglumine Anti-Emetic 265121-04-8 31484
Ketoconazole Anti-Fungal 65277-42-1 17290 CEP Approved
Lercanidipine Anti-Hypertensive 100427-26-7
Lurasidone Hydrochloride Anti-Psychotic 367514-88-3 29163
Misoprostol Anti-Ulcerant 59122-46-2 21188 CEP Approved
Monosulfiram Ectoparasiticide 95-05-6
Perindopril Tert-butylamine ACE Inhibitor 107133-36-8 28144 CEP Approved
Pramipexole Dihydrochloride Monohydrate Anti-Parkinson 191217-81-9 30186 CEP Approved
Rivaroxaban Anti-coagulant 366789-02-8 30403
Spironolactone Diuretics 52-01-7
Trazodone Hydrochloride Anti-depressant 25332-39-2 20920 ASMF
Verapamil Hydrochloride Anti-Hypertensive 152-11-4 16605 CEP Approved
Dapagliflozin (S)-Propanediol Monohydrate (1:1:1) Anti-diabetic 960404-48-2 033282
Dexlansoprazole Anti-Ulcerant 138530-94-6
Droxidopa Anti-Parkinson 23651-95-8
Mirabegron Urinary Incontinence 223673-61-8 033281
Paliperidone Palmitate Anti-Psychotic 199739-10-1 032599
Tetrabenazine Hyperkinetic Movement Disorder 58-46-8 032450
Empagliflozin Anti-diabetic 864070-44-0
Varenicline Tartrate Nicotinic Antagonist 375815-87-5
Vortioxetine Hydrobromide Anti-depressant 960203-27-4
Mebeverine Hydrochloride Anti-Spasmodic 2753-45-9 ASMF
Amiodarone Hydrochloride Anti-Arrhythmic 19774-82-4 21694 CEP Approved
Aciclovir Anti-Viral 59277-89-3 25389
Azilsartan medoxomil potassium Anti-Hypertension 863031-24-7 35770 CEP Approved
Metaxalone Muscle Relaxant 1665-48-1 27105
Sulindac NSAID 38194-50-2 26004
Tramadol Hydrochloride Analgesic 36282-47-0 24954
CEP Approved CEP Approved
CEP Applied CEP Applied
APIs (Under Development)
Product Name Category Name CAS NO
Canagliflozin Hemihydrate Anti-diabetic 928672-86-0
Linagliptin Anti-diabetic 668270-12-0
Apixaban Anti-coagulant 503612-47-3
Apremilast Anti-arthritic/Anti-psoriasis 608141-41-9
Desvenlafaxine Succinate Monohydrate Anti-depressant 386750-22-7
Sugammadex Sodium General Anaesthesia 343306-79-6
Edoxaban Anti-coagulant 1229194-11-9
CEP Approved CEP Approved
CEP Applied CEP Applied
Our range of Developed Peptide API products
Product Name Category Name CAS NO US-DMF CEP
Buserelin acetate Peptide 68630-75-1 CEP Approved
Calcitonin Salmon acetate Peptide 47931-85-1 CEP Approved
Carbetocin acetate Peptide 37025-55-1 ASMF
Cetrorelix acetate Peptide 145672-81-7 34552 ASMF
Desmopressin acetate Peptide 62288-83-9 22871
Gonadorelin acetate Peptide 499785-55-6
Gonadorelin diacetate* Peptide 33515-09-2
Goserelin acetate Peptide 145781-92-6
Leuprolide acetate Peptide 74381-53-6 25128 CEP Approved
Octreotide acetate Peptide 79517-01-4
Oxytocin acetate Peptide 50-56-6 26517 CEP Approved
Somatostatin acetate Peptide 54472-66-1 CEP Approved
Terlipressin acetate Peptide 14636-12-5 ASMF
Tetracosactide acetate Peptide 16960-16-0
Vasopressin acetate Peptide 113-79-1 32146
CEP Approved CEP Approved
CEP Applied CEP Applied
Peptide APIs (Under Development)
Product Name Category Name CAS NO
Abaloparatide acetate Peptide 247062-33-5
Atosiban acetate Peptide 914453-95-5
Corticotropin acetate Peptide 12427-33-7
Degarelix acetate Peptide 934016-19-0
Glatiramer acetate Peptide 386750-22-7
Glucagon acetate Peptide 16941-32-5
Lanreotide acetate Peptide 127984-74
Linaclotide acetate Peptide 851199-60-5
Liraglutide acetate Peptide 204656-20-2
Plecanatide acetate Peptide 467426-54-6
Semaglutide acetate Peptide 910463-68-2
Teduglutide acetate Peptide 197922-42-2
Triptorelin acetate Peptide 140194-24-7
CEP Approved CEP Approved
CEP Applied CEP Applied

Disclaimer

Piramal Pharma Limited (Company) does not offer or supply for commercial use, Products protected under valid patents,where the sale of such products constitutes a patent infringement. Only research & development quantities of such products are manufactured and offered for the purpose of regulatory submissions in India and/or other jurisdiction, wherever such regulatory exemptions exist, according to Section 107A of the Indian Patent Act and the corresponding provision of the Patent Act of the respective jurisdiction. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Piramal makes no warranty as to the completeness or accuracy of the information provided herein. Furthermore, no information in this catalogue - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. In particular, nothing in this catalogue should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.